Literature DB >> 34218288

Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion.

Koorosh Haghayeghi1, Shaolei Lu1, Andres Matoso2, Stephen F Schiff3, Catrina Mueller-Leonhard4, Ali Amin5,6.   

Abstract

Urothelial carcinoma is subdivided into luminal (L), basal (B), and p53-wild-type (WT) molecular subtypes, with basal and p53-WT groups showing more aggressive course and poor treatment response, respectively. The literature on molecular subtypes of UC includes a mixture of different stages. We investigated the molecular profile and outcome of pure cohort of muscle invasive bladder carcinoma (MIBC) considering two distinct patterns of muscularis propria (MP) invasion. Forty-three cystectomies harboring stage pT2 were retrospectively identified in 18 years. MP invasion was subclassified into patterns 1 (tumor encasing intact detrusor muscle bundles) and 2 (tumor dissecting/replacing detrusor muscle). Using IHC, B/L phenotypes, p53, and Ki67 were assessed, and survival data was collected. Pattern 1 invasion was noted in 16 (37%) and pattern 2 in 27 (63%), with mean age of pattern 1 being 10 years younger. B/L phenotypes were successfully determined in 83.7%; 48.8% and 34.8% revealed L and B phenotypes, respectively (indeterminate phenotype in 16.4%). Pattern 1 was associated with L phenotype (GATA3 and HER-2 expressions: p = 0.02 & p = 0.04, respectively). Ki67 ≥ 5/10HPF was noted in pattern 2 and B phenotype (p = 0.03). B phenotype showed association with p53-WT (p = 0.007). In median follow-up of 60.7 months, 63.6% of pattern 1 cases were alive without disease compared to 32% of pattern 2 (not significant). A panel of CK20 and GATA3 for luminal and CK5/6 and CK14 for basal subtypes can provide reliable molecular classification in UC. Also, morphology of MIBC can predict the molecular phenotype and the behavior of the UC.

Entities:  

Keywords:  Basal; Luminal; Molecular subtypes; Muscle invasive bladder cancer; Urothelial carcinoma

Year:  2021        PMID: 34218288     DOI: 10.1007/s00428-021-03145-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  3 in total

Review 1.  Radical cystectomy and orthotopic bladder substitution: surgical tricks and management of complications.

Authors:  L Izquierdo; D M Bolton; N Lawrentschuk
Journal:  Minerva Urol Nefrol       Date:  2013-12       Impact factor: 3.720

2.  Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma.

Authors:  David Lindgren; Gottfrid Sjödahl; Martin Lauss; Johan Staaf; Gunilla Chebil; Kristina Lövgren; Sigurdur Gudjonsson; Fredrik Liedberg; Oliver Patschan; Wiking Månsson; Mårten Fernö; Mattias Höglund
Journal:  PLoS One       Date:  2012-06-07       Impact factor: 3.240

3.  Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.

Authors:  Vipulkumar Dadhania; Miao Zhang; Li Zhang; Jolanta Bondaruk; Tadeusz Majewski; Arlene Siefker-Radtke; Charles C Guo; Colin Dinney; David E Cogdell; Shizhen Zhang; Sangkyou Lee; June G Lee; John N Weinstein; Keith Baggerly; David McConkey; Bogdan Czerniak
Journal:  EBioMedicine       Date:  2016-08-25       Impact factor: 8.143

  3 in total
  2 in total

Review 1.  Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation.

Authors:  Francesca Sanguedolce; Magda Zanelli; Andrea Palicelli; Stefano Ascani; Maurizio Zizzo; Giorgia Cocco; Lars Björnebo; Anna Lantz; Matteo Landriscina; Vincenza Conteduca; Ugo Giovanni Falagario; Luigi Cormio; Giuseppe Carrieri
Journal:  Int J Mol Sci       Date:  2022-07-16       Impact factor: 6.208

Review 2.  Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression.

Authors:  Francesca Sanguedolce; Magda Zanelli; Andrea Palicelli; Stefano Ascani; Maurizio Zizzo; Giorgia Cocco; Lars Björnebo; Anna Lantz; Ugo Giovanni Falagario; Luigi Cormio; Giuseppe Carrieri
Journal:  Int J Mol Sci       Date:  2022-07-15       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.